Providing independent and actionable insights on emerging best practice in Pharmaceutical commercialization including- review or create best in class product launch plans- creating winning commercial services partnerships- accelerating development of senior pharmaceutical executives through coaching and mentorship

Teaching, coaching, and mentoring MBA and Undergraduate students at the Kenan Flagler Business school.

Recruited to establish and lead strategic partnership and new business of key accounts across the clinical, commercial, consulting, and capital businesses. Full P&L accountability for $200 million in revenues. Managed a team of 20. Member of Strategic Commercial Team. Reported to SVP, Global Sales.

VP, Immunology Unit - US Commercial 2009 – 2010Built and led new business unit dedicated to commercialization of biopharmaceuticals, a new priority for corporate’s global strategic plan with a target of $3.2 billion by 2020. Reported to President, US Commercial.VP, HIV - US Commercial 2001 – 2009Full P&L responsibility for autonomous HIV division with $1.6 billion sales. Managed a staff of 140 and a $75 million sales and marketing budget. Reported to President, US Commercial.VP, R&D Product Development - GlaxoWellcome 1999 – 2001Global leadership of new product development division in metabolic, cardiovascular, and oncology that included commercial and medical teams responsible for Phase IIb through to launch. Managed a staff of 80 across US | UK and a clinical development budget of $220 million.VP, R&D Product Development - Oncology | stroke product development 1998 – 1999 Regional Business Director - $200 million P&L responsibility for regional business 1995 – 1998Director of Respiratory Marketing - Leadership for $450 million respiratory franchise 1994 – 1995International Product Management – Directed Zantac patent expiration strategy 1992 – 1994Director of Sales & Marketing, Glaxo Australia - Enabling Zantac to become #1 product 1987 – 1992 Group Product Manager, Respiratory Products, Sales Training and Field Sales 1981 – 1987Glaxo Holdings Accelerated Development Intake 1979 –1981